Fig. 2: Kaplan-Meier plots comparing ELN 2022 risk groups to AML with myelodysplasia-related gene mutations. | Leukemia

Fig. 2: Kaplan-Meier plots comparing ELN 2022 risk groups to AML with myelodysplasia-related gene mutations.

From: Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

Fig. 2

Patients from the entire cohort were retrospectively assigned to ELN 2022 risk groups. Patients within the ELN 2022 adverse risk group that had MR gene mutation were treated as a separate group for this Kaplan-Meier analysis: Event-free survival (EFS, panel A), relapse-free survival (RFS, panel B), and overall survival (OS, panel C). Log rank p values are reported for the distinction between patients with MR gene mutation and patients with ELN 2022 adverse risk (MR gene mutation excluded).

Back to article page